NTRK1 and neoplasm: As shown in Fig. 7, the targeted drug (sunitinib) inhibits receptor tyrosine kinases (RTKs), where certain receptor tyrosine kinases are involved in tumour growth, pathological blood vessel formation and tumour metastasis.